[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peritoneal-metastases-from-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peritoneal-metastases-from-gastric-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100603205","phase-2-interact-stomach-ii-100603205",false,"NCT07133490","INTERACT Stomach-II","Intraperitoneal Irinotecan Combined With Systemic Therapy for Patients With Gastric Peritoneal Metastases: A Phase II, Multicenter Study","Inclusion Criteria:\n\n* Histologically confirmed gastric cancer or gastroesophageal junction adenocarcinoma\n* Pathologically and clinically confirmed diagnosis of macroscopic peritoneal metastases (defined as PCI score ≥ 1)\n* WHO-performance score of 0 to 1 with a life expectancy greater than or equal to three months\n* Aged 18 years or older\n* Written informed consent according to the ICH-GCP and national\u002Flocal regulations\n\nExclusion Criteria:\n\n* Distant metastases other than peritoneal metastases or metastatic lymph nodes\n* Prior palliative systemic therapy for gastric cancer\n* Prior (neo)-adjuvant systemic therapy for gastric cancer within the six months before enrolment in this study\n* Severe symptomatic ascites requiring monthly recurrent therapeutic paracentesis\n* Homozygous dihydropyrimidine dehydrogenase (DPD) deficiency\n* Any contra-indication for the (planned) systemic chemotherapy (e.g. active infection, serious concomitant disease, severe allergy, persistent neurologic toxicity after (neo-)adjuvant oxaliplatin based systemic therapy), as determined by the treating medical oncologist\n* Inadequate organ functions (defined as a hemoglobin \\\u003C5.0 mmol\u002Fl, an absolute neutrophil count \\\u003C1.5 x 109\u002Fl, platelet count \\\u003C100 x 109\u002Fl, creatinine clearance \\\u003C30 ml\u002Fmin, bilirubin \\>2x ULN and liver transaminases \\>2.5x ULN)\n* Pregnant or lactating women\n* Concomitant participation in any clinical study that could modify the outcomes relevant to this study\n* Absence of assurance of compliance with the protocol","ALL",{"count":18,"type":19},55,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part. The aim is to test whether a new combination treatment is feasible for patients with gastric peritoneal metastases (PM). The treatment includes chemotherapy (intraperitoneal irinotecan and standard systemic therapy such as CAPOX or FOLFOX), and may also include nivolumab or trastuzumab, depending on biomarker results.",[25],"Peritoneal Metastases From Gastric Cancer",[27,28,29,30],"Gastric cancer","Peritoneal metastases","Intraperitoneal chemotherapy","Irinotecan","RECRUITING","2026-05-28",{"date":34,"type":35},"2026-06-01","ACTUAL",{"date":37,"type":35},"2025-10-01",{"date":39,"type":19},"2028-07-01",{"name":41,"class":42},"Erasmus Medical Center","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100635742","phase-2-lm-302-and-s-1-plus-intraperitoneal-paclitaxel-with-or-without-cadonilimab-for-claudin-182-positive-gastric-or-gastroesophageal-junction-adenocarcinoma-with-peritoneal-metastasis-a-prospective-exploratory-study-100635742","NCT07556640","LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study","LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis: a Prospective, Exploratory Study","Inclusion Criteria:\n\n* Histologically confirmed gastric or gastroesophageal junction adenocarcinoma with her 2 (-), and without the history of resection of primary or metastatic lesion;\n* Age ≥ 18 years at registration;\n* Peritoneal metastases from gastric cancer requiring definitive diagnosisby laparoscopy, and without gastric outflow tract obstruction andintestinal obstruction;\n* Claudin 18.2 positive (≥ 25%, moderate to strong staining);\n* Eastern Cooperative Oncology Group (ECOG) score ≤ 1;\n* Expected life expectancy \\> 3 months;\n* Adequate bone marrow, liver, and renal functions.\n\nExclusion Criteria:\n\n* Presence of distant metastases other than peritoneal metastasis at the time of enrollment;\n* Pregnant or breastfeeding women;\n* Prior treatment with Claudin 18.2 targeted therapy;\n* History of other malignancies within the past 5 years, except for cured skin cancer or cervical carcinoma in situ;\n* History of uncontrolled epilepsy, central nervous system disease, or mental disorder that, in the investigator's judgment, may interfere with signing informed consent or compliance with oral medication.\n* Clinically significant active heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or higher congestive heart failure, severe arrhythmia requiring medication, or myocardial infarction within the past 12 months;\n* Upper gastrointestinal obstruction, abnormal physiological function, or malabsorption syndrome that may affect S 1 absorption;\n* Known peripheral neuropathy ≥ NCI CTC AE grade 1. However, patients with loss of deep tendon reflexes (DTR) alone may be included;\n* Organ transplantation requiring immunosuppressive therapy;\n* Severe uncontrolled recurrent infection or other severe uncontrolled concomitant diseases;\n* Moderate or severe renal impairment (creatinine clearance ≤ 50 ml\u002Fmin) or serum creatinine above the upper limit of normal;\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency;\n* Active hepatitis (for hepatitis B: HBsAg positive and HBV DNA ≥ 500 IU\u002Fml; for hepatitis C: HCV antibody positive and HCV viral load \\> upper limit of normal);\n* Psychiatric disorder that makes the patient unable to comply with treatment;\n* Allergy to paclitaxel or any component of the study drugs;\n* History or evidence of any disease, condition, treatment, or laboratory abnormality that could interfere with the study results or the patient's full participation, or any other condition that, in the investigator's opinion, makes the patient unsuitable for enrollment.","18 Years",{"count":52,"type":19},74,[22],"In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.",[56,25,57],"Gastric Cancer Stage IV","Gastric or Esophagogastric Junction Adenocarcinoma",[27,59,60,61,62,57],"Peritoneal metastasis","Claudin 18.2","Cadonilimab","Paclitaxel","2026-04-24",{"date":65,"type":35},"2026-04-29",{"date":67,"type":35},"2026-04-17",{"date":69,"type":19},"2029-04-30",{"name":71,"class":42},"Ruijin Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":72},"100617050","hyperthermic-intraperitoneal-chemoperfusion-hipec-in-gastric-cancer-100617050","NCT07313579","Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","G-PEC","Inclusion Criteria:\n\n1. Age 18-80\n2. Hystologicaly proven gastric adenocarcinoma\n3. ECOG status 0-1\n4. Written consent to participate in the study\n5. Medically and technically operable gastric tumor\n6. Only T4a or T4b tumours with any peritoneal cytology status\n7. Cytologically positive peritoneal washings (cyt+) with any T and N criteria\n8. Adequate haemopoetic, renal and hepatic function (Hb \\> 120, PLT \\> 150\\*10\\^9\u002Fl, ALT \\\u003C 60, AST \\\u003C40, total bilirubin \\\u003C 21 µmol\u002Fl, Creatinine clearance (male - 90-140, female - 80-130 ml\u002Fmin)\n\nExclusion Criteria:\n\n1. Pregnancy\u002Fbreastfeeding\n2. ECOG status 2-4\n3. Concomitant malignancy\n4. Mitomycin and\u002For Cisplatin hypersensitivity\n5. Uncontrollable chronic diseases\n6. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years.\n7. Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes)\n8. History of allergic reactions associated with cisplatin and Mitomycin C\n9. Patients with psychiatric illness\u002Fsocial situations with impaired compliance\n10. •Refusal to participate","80 Years",{"count":83,"type":19},200,"OBSERVATIONAL","The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.",[87,88,25,89],"Gastric Cancer (GC)","HIPEC","Hyperthermic Intraperitoneal Chemoperfusion",[27,88,89,91,92,93,94,95,96,97,98,99,100,101],"FLOT","Lymphadenectomy","Gastrointestinal Neoplasms","Digestive System Neoplasms","Gastrointestinal Diseases","Stomach Diseases","Stomach Neoplasms","Chemotherapy, Adjuvant","Combined Modality Therapy","Drug Therapy","Surgical Procedures","2026-01-10",{"date":104,"type":35},"2026-01-13",{"date":106,"type":35},"2025-12-01",{"date":108,"type":19},"2035-12-01",{"name":110,"class":42},"Ukrainian Society of Clinical Oncology"]